Literature DB >> 9684921

Topoisomerase II and the response to antileukemic therapy.

S H Kaufmann1, S D Gore, C B Miller, R J Jones, L A Zwelling, E Schneider, P J Burke, J E Karp.   

Abstract

A number of recent studies have investigated the expression of topoisomerase II in clinical leukemia specimens. Here we outline the rationale for these studies, identify potential pitfalls, summarize recent results, and discuss unanswered questions in this area.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9684921     DOI： 10.3109/10428199809068560

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  8 in total

1.  XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.

Authors:  Parvathi Ranganathan; Trinayan Kashyap; Xueyan Yu; Xiaomei Meng; Tzung-Huei Lai; Betina McNeil; Bhavana Bhatnagar; Sharon Shacham; Michael Kauffman; Adrienne M Dorrance; William Blum; Deepa Sampath; Yosef Landesman; Ramiro Garzon
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

2.  Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405.

Authors:  Ryan P Bender; Amy-Joan L Ham; Neil Osheroff
Journal:  Biochemistry       Date:  2007-02-14       Impact factor: 3.162

3.  Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.

Authors:  Ryan P Bender; Michael J Jablonksy; Mohammad Shadid; Ian Romaine; Norma Dunlap; Clemens Anklin; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2008-03-21       Impact factor: 3.162

4.  Bioflavonoids as poisons of human topoisomerase II alpha and II beta.

Authors:  Omari J Bandele; Neil Osheroff
Journal:  Biochemistry       Date:  2007-04-26       Impact factor: 3.162

5.  Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).

Authors:  Lauren M Congdon; Alan Pourpak; Aluvia M Escalante; Robert T Dorr; Terry H Landowski
Journal:  Biochem Pharmacol       Date:  2007-11-04       Impact factor: 5.858

6.  Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.

Authors:  Ryan P Bender; Neil Osheroff
Journal:  Chem Res Toxicol       Date:  2007-05-22       Impact factor: 3.739

7.  Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.

Authors:  Amy M Wilstermann; Ryan P Bender; Murrell Godfrey; Sungjo Choi; Clemens Anklin; David B Berkowitz; Neil Osheroff; David E Graves
Journal:  Biochemistry       Date:  2007-06-20       Impact factor: 3.162

8.  Cytotoxic effect and molecular docking of 4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemicarbazide--a novel topoisomerase II inhibitor.

Authors:  Agata Siwek; Paweł Stączek; Monika Wujec; Krzysztof Bielawski; Anna Bielawska; Piotr Paneth
Journal:  J Mol Model       Date:  2012-11-28       Impact factor: 1.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.